Observational studyReproductive biology and endocrinology : RB&E2025
Automated AI for real-time sperm selection in ICSI: reducing variability and studying the role of sperm in embryo development.
Observational study in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence-Driven Reproductive Bioengineering: Integrating Fertility Diagnostics, Organ-on-Chip Systems, Cryobiology and Epigenetic Safety for Precision Reproductive Medicine.Bioengineering (Basel, Switzerland) · 2026Review
- Implementation readiness of artificial intelligence inFrontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe application of Artificial Intelligence (AI) to sperm selection during Intracytoplasmic Sperm Injection (ICSI) procedures represents one of the most innovative advances in assisted reproductive technology (ART). Traditional sperm selection relies heavily on the subjective assessment of embryologists, which can lead to variability in outcomes. This study aimed to evaluate the performance of an AI-based software, Sperm ID (SiD™) v.1.0, for sperm selection during ICSI and to compare its outcomes with those obtained by experienced embryologists. Additionally, the study assessed the potential impact of sperm and oocyte quality, particularly in autologous versus donor oocyte cycles.
methodsA single-center, blind, observational study was conducted involving 102 infertile couples-60 undergoing treatment with autologous oocytes and 42 using oocytes from a donation program. Semen samples were analyzed in real time with SiD™ v.1.0, a software that quantifies progressive motility parameters and assigns each sperm a categorical score ('Best,' 'Good,' 'Medium,' or 'low'). Spermatozoa and oocytes were individually tracked from injection to embryo development. Oocyte quality was retrospectively analyzed using another AI tool, Magenta IVF R3.0. The performance of the Artificial Intelligence Sperm Selection (AISS) system was compared with that of senior embryologists (> 300 ICSI cycles/year). Statistical analysis included descriptive statistics and inferential tests to compare fertilization and embryo development rates across sperm categories and between autologous and donor cycles.
resultsBiological outcomes-such as fertilization and blastocyst development-were generally similar across all sperm quality categories. However, in cycles with autologous oocytes, the use of top-quality sperm ('Best' category) was associated with a significantly higher blastocyst formation rate. In contrast, no significant differences were observed in donor oocyte cycles, regardless of sperm quality. The AISS system demonstrated comparable performance to that of senior embryologists, with similar fertilization and embryo development rates.
conclusionsThe study highlights the promising role of AI-based tools in standardizing and enhancing sperm selection during ICSI. While AI-driven sperm selection showed limited impact in donor cycles, it may offer a distinct advantage in cases involving compromised oocyte quality. Furthermore, AISS may improve laboratory efficiency and support junior embryologists by reducing selection time and increasing procedural consistency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.